Dublin-based Mallinckrodt company has decided it needs a U.S. campus to consolidate workers picked up in an M&A spree, as well as some more manufacturing,…

Mylan is facing the prospect of investigations--as well as public criticism--following years of price increases on its big-selling EpiPen.

Amgen was aiming to launch its cholesterol-fighter Repatha quickly in India. But a panel of CV and renal specialists blocked the PCSK9 drug instead.

Despite a renewed push by health officials to promote HPV vaccination, a new poll finds that only a minority of parents believe laws requiring the vaccines “…

This year’s stock market hasn’t been easy for pharma. Unwelcome news has sent some drugmakers' shares tumbling--as much as 72%, in one notorious case.

Valeant CEO Joseph Papa has filled another link in the company's executive rank, hiring Zoetis and Warner Chilcott veteran Paul S. Herendeen, as chief…

Instagram has just made social media easier and safer for pharma. Instagram Stories, 24-hour disappearing video and photo narrative postings, allow comments to…

Boehringer's Pradaxa won an edge on its new-age anticoagulant rivals last year when the FDA approved a reversal agent. It'll hang onto that edge, at…